Skip to content
Lower risk Drug recall · FDA · Published January 10, 2024

BE Pharmaceuticals Fosaprepitant Injection Recall: Sterility Risk After Reconstitution

BE Pharmaceuticals recalls Fosaprepitant 150mg vials due to potential sterility issues after reconstitution. This could lead to infections if used improperly. Check your vial's lot number and contact the company for details.

🇺🇸 FDA recall #D-0262-2024DrugBE Pharmaceuticals ›
Take action

Contact the company

Recalling firmBE PHARMACEUTICALS AGBundesstrasse 3 · Zug, Switzerland
✎ GovInfoNow plain-language explainer

BE Pharmaceuticals is recalling Fosaprepitant 150mg injection vials because of a lack of sterility assurance during the manufacturing process. This could cause infections if the medication is reconstituted and used improperly. Read more at govinfonow.com/recall/32887-be-pharmaceuticals-fosaprepitant-injection-recall-sterility-risk-after-reconstitution.

Source Summary by GovInfoNow · govinfonow.com/recall/32887-be-pharmaceuticals-fosaprepitant-injection-recall-sterility-risk-after-reconstitution · Updated August 17, 2026 · FDA enforcement record: FDA #D-0262-2024

Cite this page

“BE Pharmaceuticals Fosaprepitant Injection Recall: Sterility Risk After Reconstitution.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32887-be-pharmaceuticals-fosaprepitant-injection-recall-sterility-risk-after-reconstitution. Based on FDA recall #D-0262-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0262-2024%22&limit=1).

BE Pharmaceuticals AG recalled Fosaprepitant for Injection 150 mg per vial nationwide on Jan. 10, 2024, due to a lack of sterility assurance from an aseptic process simulation failure, the FDA said.

How to tell if you have it

  • Brand: BE Pharmaceuticals
  • Product: Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution
  • NDC: 71839-104-01
  • Lot code: 13D012AA
  • Expiration date: 08/31/2025
  • Quantity: 22,176 vials

The hazard

The recall addresses a lack of sterility assurance resulting from an aseptic process simulation failure. The FDA classified the recall as Class II.

Context

GovInfoNow's records show BE PHARMACEUTICALS AG has one other recall on record since Sept. 5, 2023: a Sept. 5, 2023 recall of Pantoprazole Sodium 40mg Vials due to sterility risk from vial cracks. Other recent recalls of similar products include a June 24, 2026 Reliance Pemetrexed Injection Recall for sterility risk in IV doses and a July 28, 2026 Regeneron Libtayo injection recall for lack of sterility assurance risk.

How to tell if you have this one

Check for the vial label with 'Fosaprepitant for Injection 150 mg per vial, Sterile lyophilized powder for Intravenous use only after reconstitution'. The lot number is 13D012AA and expiration date is 08/31/2025.

  • Brand
    BE Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Vial Label

    Look for the product name and lot number on the vial label to confirm if it's part of the recall.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 17 months after the firm started it.

1. Firm started the recall: Jan 10, 202412. FDA classified it Class II: Jan 25, 202423. Published in FDA’s Enforcement Report: Jan 31, 202434. FDA terminated the recall: Jun 10, 2025420242025
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this medication safe to use?

The recall indicates a potential sterility issue after reconstitution, so it's not safe to use without checking the recall status.

What should I do if I have this medication?

Contact BE Pharmaceuticals at 203 New Edition Court, Cary, NC 27511 for further instructions.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0262-2024 (January 10, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0262-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA